<p>Thawed PBMCs from SPMS patients were stained for NK cells and major subsets using CD56 and CD16. (A) Representative flow cytometry plots show the NK cell gating strategy and MX-induced changes over time in NK cells. (B) Shows the population percentages. After six months of treatment, the NK cell population was significantly enriched and then decreased from six to 12 months of treatment. The CD56<sup>dim</sup> and CD56<sup>bright</sup> NK cells subsets were significantly increased after six months of treatment, but no difference was detected from six to 12 months. (C) Frequencies of NK cells and NK cell subsets in SPMS patients before and after MX treatment compared to the frequency observed in matched healthy individuals. (D) Shows absol...
<p><b>A</b>) PBMCs from two normal (healthy) donors (N1 and N2) and from the patient (P) were staine...
BACKGROUND: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in t...
<p><b>A</b>) Percentage of CD16<sup>+</sup>, CD57<sup>+</sup> and CD158<sup>+</sup> cells before (−)...
<p>Thawed PBMCs from MX-treated SPMS patients were stained for expression of CD62L, CD27, CD57, NKp3...
<p>Thawed PBMCs from SPMS patients stratified into responders and non-responders to MX, were stained...
<p>Peripheral blood samples from SPMS patients were surface stained for CD16, CD19, CD14, CD3, CD4, ...
<p>A: CD56<sup>dim</sup>CD16<sup>+</sup> (left panel) cells and CD56<sup>hi</sup>CD16<sup>−</sup> (r...
<p>A, B. NK cell was expressed as CD3–CD16+CD56+ cells in PBMCs. C. The frequencies of NK cells in M...
<p>PBMC from 20 healthy controls were stimulated in culture with the cell line K562 or PMA-I in the ...
<p>A-B) The frequency of CD16<sup>pos</sup> NK cells correlates with the duration of ART in years an...
<p>(<b>A</b>) Ionomycin treatment reduces the expression of CD56 on NK cells. (<b>B</b>) NK cells we...
Background: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in t...
<p><i>A</i>, Mean expansion of CD3<sup>neg</sup>/CD16-or-56<sup>pos</sup> NK cells from 22 donors ex...
<p><b>(A) Percentages of expanded NK (CD3<sup>-</sup>) and T (CD3<sup>+</sup>) cells, indicated as p...
In recent years, it has been shown that under certain conditions cytostatic agents (chemotherapy and...
<p><b>A</b>) PBMCs from two normal (healthy) donors (N1 and N2) and from the patient (P) were staine...
BACKGROUND: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in t...
<p><b>A</b>) Percentage of CD16<sup>+</sup>, CD57<sup>+</sup> and CD158<sup>+</sup> cells before (−)...
<p>Thawed PBMCs from MX-treated SPMS patients were stained for expression of CD62L, CD27, CD57, NKp3...
<p>Thawed PBMCs from SPMS patients stratified into responders and non-responders to MX, were stained...
<p>Peripheral blood samples from SPMS patients were surface stained for CD16, CD19, CD14, CD3, CD4, ...
<p>A: CD56<sup>dim</sup>CD16<sup>+</sup> (left panel) cells and CD56<sup>hi</sup>CD16<sup>−</sup> (r...
<p>A, B. NK cell was expressed as CD3–CD16+CD56+ cells in PBMCs. C. The frequencies of NK cells in M...
<p>PBMC from 20 healthy controls were stimulated in culture with the cell line K562 or PMA-I in the ...
<p>A-B) The frequency of CD16<sup>pos</sup> NK cells correlates with the duration of ART in years an...
<p>(<b>A</b>) Ionomycin treatment reduces the expression of CD56 on NK cells. (<b>B</b>) NK cells we...
Background: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in t...
<p><i>A</i>, Mean expansion of CD3<sup>neg</sup>/CD16-or-56<sup>pos</sup> NK cells from 22 donors ex...
<p><b>(A) Percentages of expanded NK (CD3<sup>-</sup>) and T (CD3<sup>+</sup>) cells, indicated as p...
In recent years, it has been shown that under certain conditions cytostatic agents (chemotherapy and...
<p><b>A</b>) PBMCs from two normal (healthy) donors (N1 and N2) and from the patient (P) were staine...
BACKGROUND: Natural cytotoxicity, mediated by natural killer (NK) cells plays an important role in t...
<p><b>A</b>) Percentage of CD16<sup>+</sup>, CD57<sup>+</sup> and CD158<sup>+</sup> cells before (−)...